Prenetics Global Earnings Call Transcripts
Fiscal Year 2026
-
Panelists from leading wellness and consumer brands discussed the importance of authentic influencer partnerships, emphasizing that genuine product use, equity alignment, and scientific validation drive long-term success. Data-driven tracking, multi-year deals, and a mix of macro and micro-influencers were highlighted as best practices.
-
IM8 has rapidly scaled to $100 million ARR in under a year by focusing on a unique all-in-one supplement, leveraging celebrity ambassadors, and a robust direct-to-consumer model. Strong retention, global reach, and aggressive digital marketing—powered by AI—support ambitious growth targets and new product launches in 2026.
-
IM8 drove explosive growth, reaching $120 million ARR in its first year and fueling a strategic focus on global DTC expansion. With robust liquidity, premium products, and strong ambassador partnerships, the brand projects $180–$200 million revenue in 2026 and aims for profitability by Q4 2027.
-
IM8, co-founded with David Beckham, has become the fastest-growing supplement brand, reaching $120 million ARR in under a year and projecting $180–$200 million revenue for 2026. With strong financials, global expansion, and high-profile ambassadors, the company is positioned for continued rapid growth.
Fiscal Year 2025
-
Record 2025 revenue of $92.4M, up 480% year-over-year, driven by IM8's explosive growth and global expansion. Strategic divestitures strengthened liquidity to $171M with no debt. 2026 guidance targets $180M-$200M IM8 revenue and 60% gross margin, with profitability expected by Q4 2027.
-
IM8, a premium supplement brand, has achieved $100 million ARR in 11 months and projects $180-$200 million in 2025 revenue, driven by global direct-to-consumer sales and high-profile ambassadors. The company is divesting legacy assets to focus on IM8, maintains a strong balance sheet, and employs a Bitcoin treasury strategy.
-
Q3 saw revenue surge 568% year-over-year to $23.6M, driven by IMA's rapid global expansion and 76% sequential growth. Gross margin rose to 60%, and adjusted EBITDA loss narrowed to $2.1M, with strong liquidity and no debt supporting aggressive scaling.